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Abstract
Background/aims: Serious adverse event reporting guidelines have largely been developed for pharmaceutical
trials. There is evidence that serious adverse events, such as psychological distress, can also occur in non-
pharmaceutical trials. Managing serious adverse event reporting and monitoring in palliative care non-
pharmaceutical trials can be particularly challenging. This is because patients living with advanced malignant or
non-malignant disease have a high risk of hospitalisation and/or death as a result of progression of their disease
rather than due to the trial intervention or procedures. This paper presents a number of recommendations for
managing serious adverse event reporting that are drawn from two palliative care non-pharmacological trials.
Methods: The recommendations were iteratively developed across a number of exemplar trials. This included
examining national and international safety reporting guidance, reviewing serious adverse event reporting
procedures from other pharmacological and non-pharmacological trials, a review of the literature and collaboration
between the ACTION study team and Data Safety Monitoring Committee. These two groups included expertise in
oncology, palliative care, statistics and medical ethics and this collaboration led to the development of serious
adverse event reporting procedures.
Results: The recommendations included; allowing adequate time at the study planning stage to develop serious
adverse event reporting procedures, especially in multi-national studies or research naïve settings; reviewing the
level of trial oversight required; defining what a serious adverse event is in your trial based on your study
population; development and implementation of standard operating procedures and training; refining the
reporting procedures during the trial if necessary and publishing serious adverse events in findings papers.
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Conclusions: There is a need for researchers to share their experiences of managing this challenging aspect of trial
conduct. This will ensure that the processes for managing serious adverse event reporting are continually refined
and improved so optimising patient safety.
Trial registration: ACTION trial registration number: ISRCTN63110516 (date of registration 03/10/2014).
Namaste trial registration number: ISRCTN14948133 (date of registration 04/10/2017).
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Background
More research is needed in palliative care to improve
the evidence base that underpins clinical practice [1], es-
pecially as the need for palliative care is predicted to in-
crease substantially by 2060 [2]. There is a
commensurate need to increase the number of high
quality trials in palliative care as they are an optimal de-
sign for testing the effectiveness of treatments and thera-
peutic interventions [3, 4]. Many interventions and
treatments commonly used in palliative care have little
supporting trial evidence [5]. Clinical trials, as well as
testing effectiveness, also need to assess whether the
novel treatment or intervention is in fact safe [6].
Safety reporting procedures aim to capture any adverse
events that may arise during a trial [7]. Trial protocols
should contain details of how adverse events are to be
identified, collected, assessed, reported and managed [8].
Findings papers should also report on the adverse events
that have occurred during a trial [7, 9, 10]. There are
internationally agreed definitions and reporting proce-
dures for pharmacological trials [11]. In a clinical trial,
an adverse event is any untoward medical occurrence
that is experienced by a trial participant which is not ne-
cessarily related to the intervention [12]. The adverse
event is classified as serious when, at any dose, it results
in: death, is life-threatening, requires inpatient hospital-
isation or prolongation of existing hospitalisation, results
in persistent or significant disability/incapacity or is a
congenital anomaly/birth defect [12].
Monitoring of adverse events during a trial is key to
ensuring patient safety but structures and processes, in-
cluding nomenclature, can vary depending on the
funder, trial type and jurisdiction [13]. Generally, an in-
ternal study team or group is responsible for the day to
day running of the trial while a Trial Steering Commit-
tee, made up of largely independent members including
patient representation, provides additional scrutiny [13].
An independent Data Safety Monitoring Committee may
also be set up, more commonly in pharmaceutical trials,
to monitor un-blinded safety and efficacy data and if re-
quired recommend the trial is stopped to safeguard the
interests of participants [13, 14]. Ethical approval pro-
cesses can vary internationally [15] but a research ethics
committee’s role is to review the potential risks of a
study [11]. Requirements for reporting adverse events to
research ethics committees can vary between nations
[16] but international guidance recommends that unex-
pected serious adverse events related to the intervention
(SUSARs) be promptly reported [11].
There is evidence that serious adverse events, such as
psychological distress, can occur in non-pharmacological
trials [17]. This paper focuses on serious adverse event
reporting in palliative care non-pharmaceutical trials as
there is a lack of guidance for researchers. This is also
an issue outside palliative care. One review of psycho-
logical trials highlighted an over reliance on the defin-
ition used in pharmacological trials and that researchers
did not identify which serious adverse events might
likely arise from a specific intervention in a particular
population [18].
The definition of a palliative care population can vary
[19, 20] but in this paper a palliative care trial focuses
on those patients living with advanced malignant or
non-malignant disease and their family carers. This
group of patients are viewed as vulnerable as they have
complex physical, psychosocial and spiritual needs and
can have a limited life expectancy [21]. They are cared
for in diverse clinical settings and receive care from spe-
cialist and/or generalist palliative care professionals.
Non-pharmacological palliative care interventions are
heterogeneous. Typically, they are complex interventions
that reflect a holistic and multi-disciplinary approach to
care [22] with quality of life and/or symptom control be-
ing the primary outcome [22–24] rather than survival or
disease response [25]. Interventions may be taken from
other patient populations and applied to those living
with advanced disease [26] or developed specifically to
meet the needs of this patient group [27]. The character-
istics of a non-pharmacological palliative care trial make
implementing serious adverse event reporting proce-
dures challenging.
The challenges of applying the standard serious ad-
verse event definitions and reporting procedures was
considered in two recent palliative care non-
pharmacological trials. The ACTION study was a cluster
randomised controlled trial assessing the effects of an
advance care planning programme on the quality of life
of patients with advanced lung or colorectal cancer. The
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trial took place in six European countries and recruited
1117 participants in the hospital setting [28]. The Nam-
aste Care study was a feasibility cluster randomised con-
trolled trial. The trial took place in nursing homes in the
UK and focused on the psychosocial Namaste Care
intervention for residents living with advanced dementia
[29]. Research Ethics Committee approval was obtained
in all six countries taking part in the ACTION study
(NRES Committee North West - Liverpool East 14/NW/
1189) and in the UK for the Namaste study (Wales Re-
search Ethics Committee 5 Bangor 17/WA/0378). Writ-
ten informed consent was obtained for all participants
with consent being provided by a proxy in the Namaste
trial as residents lacked capacity.
Given the health status of participants in the ACTION
trial and the Namaste trial, there was a relatively high
risk of death and/or hospitalisation for participants dur-
ing the study. These events were not anticipated to be
related to the receipt of the intervention or the trial pro-
cedures and similar issues have been raised in critical
care trials [30]. A challenge in both studies was how to
ensure serious adverse events related to the trial inter-
vention or procedures were recorded while preventing
unnecessary and burdensome reporting processes for
both study coordinating centre staff and clinicians.
There was a risk that reporting all serious adverse events
would result in those potentially related to the interven-
tion being missed [31]. There was also a risk that clinical
staff would not report serious adverse events because
they were not pharmaceutical trials.
This paper outlines a number of recommendations
(see Table 1) that were drawn from the learning from
these two exemplar trials. The recommendations may be
useful for others who are developing and implementing
serious adverse event reporting procedures in palliative
care non-pharmaceutical trials.
Methods
A number of strategies were used to develop the serious
adverse event reporting procedures for the ACTION
trial. Initially, the procedures of other pharmacological
and non-pharmacological trials were reviewed for guid-
ance. This was in addition to the national and inter-
national guidance available to guide serious adverse
event reporting in clinical trials [7, 8, 10, 11, 32]. This
formed the basis of the serious adverse event form used
in the study. A Data Safety Monitoring Committee was
set up, as this was a requirement in the UK, an approach
then approved by all trial consortium members. The
Data Safety Monitoring Committee recommended a pro-
active rigorous approach to the monitoring of serious
adverse events during the trial (see Table 3 for further
details). Development of the serious adverse event
reporting procedures was a collaborative process be-
tween the ACTION trial consortium and the trial’s Data
Safety Monitoring Committee. Both groups comprised a
diverse group of clinical and academic professionals
from across Europe and included expertise in oncology,
palliative care clinical practice and research, including
trials, statistics, as well as medical ethicists. This collab-
oration led to the definition of a serious adverse event in
this study (see Table 2).
During the trial, a review of the literature was carried
out to explore how the serious adverse event reporting
procedures of the ACTION study compared with other
trials of palliative care psychological interventions (see
Additional file 1). The review highlighted that there is a
lack of evidence of how serious adverse events should be
monitored in these type of studies. How the study teams
planned to manage psychological distress and deal with
concerns raised from questionnaire responses were
sometimes reported in the published trial protocols.
There was also a lack of reporting of serious adverse
events in the final reports of included studies which
could suggest that no serious adverse events have oc-
curred, they were not recognised or recorded or they
were recorded but not reported [18].
The recommendations outlined below were iteratively
developed from the learning across both trials.
The recommendations
Experience from both trials highlighted the need to fac-
tor in adequate time at the study planning stage to de-
velop serious adverse event reporting procedures that
reflected the study population, the intervention being
tested and that aligned with international, national and
local procedures. The Namaste trial also required add-
itional time as the nursing home sites had not taken part
in a previous trial and for some of the homes, this was
their first experience of research.
Defining what a serious adverse event is in your trial
The importance of defining what a serious adverse event
is in your trial based on your study population was
Table 1 Recommendations for managing serious adverse event
reporting procedures in palliative care non-pharmacological
trials
• Factor in adequate time at the study planning stage to develop
serious adverse event reporting procedures especially in a multi-
national study or for research naïve settings such as a nursing home.
• Review level of trial oversight required (see Fig. 1)
• Define what a serious adverse event is in your trial, based on your
study population, including their health state, the expected risks and
the type of events that should be reported.
• Develop documentation to support serious adverse event reporting.
• Implement serious adverse event reporting procedures.
• Monitor serious adverse events during the trial.
• Refine the reporting procedures during the trial if necessary.
• Report the serious adverse events that occur during the trial in the
final report papers.
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identified. This definition should take account of their
health status, the expected risks and the type of events
that should be reported. How this process was operatio-
nalised in the two trials is described in Table 2. In the
Namaste trial, patient and public involvement represen-
tatives provided advice on the wording of participation
information [34] and questionnaires to try and reduce
the risk of distress.
Documentation to support serious adverse event
reporting
Serious adverse event standard operating procedures
and reporting forms were developed for both trials. The
Clinical Trial Unit that was managing the Namaste trial
data had limited experience of supporting non-
pharmaceutical trials. Their standard reporting proce-
dures had to be adapted to fit the trial design and clin-
ical setting which added additional time to the study set
up process. In the ACTION trial, a form for document-
ing routine hospital admissions was produced that asked
for reason and length of admission. In both trials, a form
was created to document all deaths which included the
date and cause of death, in the ACTION trial place of
death was also documented.
Implementation of serious adverse event reporting
procedures
In the ACTION trial, oncologists and research nurses
were experienced in pharmacological trial serious ad-
verse event reporting procedures but less so in non-
pharmacological studies. Informal training was provided
at the start of study and support was available through-
out the trial and if a serious adverse event was
suspected. In the Namaste trial, nursing home staff were
unsurprisingly largely research naïve so a research man-
ual was developed to explain reporting procedures to
non-research staff. Formal research training was pro-
vided at the start of the study and support was available
throughout the trial and if a serious adverse event was
suspected.
Monitoring of serious adverse events during the trial
Multiple strategies were used to monitor serious adverse
events in both trials and reporting procedures were re-
fined during the trial as necessary (see Table 3). As rec-
ommended by the Consort guidelines [7], both passive
and active surveillance strategies were used. Passive sur-
veillance involved the recording of spontaneously re-
ported serious adverse events by patients, their proxies
or health care professionals. In the ACTION trial, active
surveillance involved the review, by the Data Safety
Monitoring Committee, of the total number of patients
screened for eligibility, who was eligible, asked for con-
sent, and included plus response rates per study arm
and per tumour type, the primary outcome measure and
hospital admission and death data in both arms of the
trial. In the Namaste trial, a review of baseline question-
naires highlighted the need to monitor patient pain
scores and guidance for highlighting concerns to the
nursing home manager was developed.
Reporting of the serious adverse events that occur during
the trial
The serious adverse events that occurred were reported
in the final report papers. In the ACTION trial, three
serious adverse events related to the intervention were
Table 2 Defining what a serious adverse event is in your trial




Advanced colorectal or lung cancer patients with an approximate
50% one-year survival rate. It would not be unexpected that pa-
tients may die or be admitted to hospital while taking part in the
trial.
Nursing home residents living with advanced dementia (FAST
score 6 or 7). In a previous study evaluating the Namaste Care
programme, early deaths (< 2 months) were not uncommon in




Patient and/or carer distress due to the intervention and/or
completion of questionnaires. The risks were expected to be
limited in those countries where advance care planning
conversations are considered to be part of routine care and
mostly validated questionnaires were being used in the study.
The anticipated risks for residents of taking part were viewed
as low as the core elements of the programme are sensory
activities that involve music, massage, colour, taste and scents.
These core elements are viewed as best practice in dementia
and end of life care. A potential risk identified was a skin
reaction to Namaste Care activities e.g. massage oils or the
actigraphy watch that was being used for data collection, with
anaphylaxis being viewed as a potential serious adverse event.
Nursing home staff completed proxy questionnaires on behalf





‘We ask you to complete this form for every event in the study
that takes a course that is significantly more unfavourable to
study participants than foreseen in the normal course of the
illness.’
*All hospital stays of at least one night and deaths in both arms
of the trial were included in reports for the Data Safety
Monitoring Committee.
Only deaths, hospitalisations, life threatening or medically
significant/important events related to the intervention or data
collection procedures were to be reported as serious adverse
events.
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reported; one patient became distressed after reading the
study information materials and two after having partici-
pated in the advance care planning conversations. They
were resolved through conversations with the patients
[35]. In the Namaste trial, there were no serious adverse
events reported but one adverse event arose from use of
the actigraph device used for data collection. Bruising
was observed on one individual, with no lasting effect
[36].
Discussion
The need to improve the quality of reporting of serious
adverse events in trials has been recognised [7, 9] but
there is a lack of practical guidance on how to manage
this process, particularly in palliative care non-
pharmacological trials. This may be because published
trial protocols and results papers may have limited space
to document these processes and/or they are challenging
to implement because of the characteristics of a pallia-
tive care trial. This paper addresses this issue by present-
ing a number of recommendations based on the lessons
learnt from managing serious adverse event reporting
procedures in two non-pharmacological trials in pallia-
tive care.
When designing a palliative care non-pharmaceutical
trial the possibility that serious adverse events may occur
should be not be dismissed and should be actively con-
sidered, including ‘worst case scenarios’. In pharmaceut-
ical trials, the potential for serious adverse events to
occur is evaluated in four phases of trial development.
Phase I trials, historically referred to as ‘toxicity trials’,
test a new drug in a small number of participants to
identify the dose range and the drug’s safety profile [16,
37]. Phase II trials evaluate safety in a larger group of
participants and set the dosage schedule for further
phases. Phase III trials are usually double blind rando-
mised controlled trials involving more participants and
they assess efficacy and serious adverse events between
intervention and control arms. Phase IV studies are post
marketing studies and evaluate serious adverse events
related to longer term use [16, 38]. The four stages of
the Medical Research Council framework for developing
complex interventions reflect the phases of drug
development [39, 40]. As discussed previously, palliative
care non-pharmaceutical trials typically involve complex
interventions. The potential for serious adverse events to
occur is something that should be explicitly explored
earlier in their development and conduct. For example,
in the feasibility/piloting stage, one of the trial’s objec-
tives should be to determine the type and consequences
of any serious adverse events related to the intervention
or study procedures prior to a definitive trial [41]. Re-
views of feasibility/pilot studies, however, show that this
is not always the case [42, 43].
This paper also contributes to the discussion regarding
trial safety oversight in the context of palliative care
non-pharmaceutical trials. Setting up a Data Safety
Monitoring Committee or Trial Steering Committee
with appropriate expertise can be time consuming, an
issue also raised in the general trial literature [44]. This
can be more challenging for international studies when
there may be a number of different local regulatory re-
quirements to incorporate into the process. The criteria
for determining the need for a Data Safety Monitoring
Committee are not well defined, even in pharmaceutical
trials [44]. Research ethics committees, as in pharma-
ceutical trials, should review whether potential serious
adverse events have been considered and how they are
going to be monitored in these type of studies [11].
The MORECare recommendations for evaluating com-
plex interventions in end of life care do not cover serious
adverse event reporting or how safety should be monitored
in this context, including the role of ethics committees and
other monitoring committees [5]. This is an area of pallia-
tive care trial methodology that requires further research.
In this context, a risk assessment matrix may help re-
searchers determine the type of oversight committee re-
quired for their trial (see Fig. 1) but this requires further
research. In the palliative care context, risks associated with
introducing the trial may also need to be considered, as this
will be dependent on the patient’s level of awareness and
the communication skills of the recruiter [45].
Conclusions
There may be a greater level of risk associated with
pharmaceutical trials but as our experience has
Table 3 Monitoring of serious adverse events during the trial
ACTION trial Namaste trial
Regular telephone and face to face contact with clinical sites.
Data Safety Monitoring Committee review of:
• Serious adverse event forms
• Items from the Quality of Life questionnaires related to distress
• Routine hospital admission and expected death information
• Total number of patients screened for eligibility, who were eligible, asked
for consent, and included plus response rates per study arm and per tumour
type
Liaison with clinical staff, as necessary, to ensure an appropriate plan of care
was put into place.
Regular telephone and face to face contact with nursing home
sites.
Review of serious adverse event forms by study coordinating
centre and findings reported to the Trial Steering Committee.
Monitoring of pain scores reported during the trial.
Study coordinating staff to report concerns to nursing home
manager if pain scores high.
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highlighted non-pharmaceutical trials are not, as is
sometimes assumed, risk free. There is a need for those
involved in non-pharmaceutical trials to share their ex-
periences of managing this challenging aspect of trial
conduct. This will ensure the procedures for managing
serious adverse events are continually refined and im-
proved so optimising patient safety, with further re-
search warranted.
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